Key facts
- ProFound Therapeutics’s last known valuation is $310.0M (Feb 2025).
- It has raised $162.7M; the latest was Later Stage VC ($50.0M) in Feb 2025.
- Notable investors include Samsung Venture Investment, Modi Ventures, Flagship Pioneering, Notley Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ProFound Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ProFound Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProFound Therapeutics
Developer of a novel therapeutic target discovery platform designed to make a profound impact on human health. The company's platform uses protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential, enabling biotech researchers to get a database of novel proteins, including their connectivity, functionality, and roles in health and disease.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 46
- Website
- profoundtx.com/
- Ownership
- Privately Held (backing)
ProFound Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProFound Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProFound Therapeutics in its N-PORT filings yet. We sweep new filings monthly.